journal article·2021-11-10

MCP-1-Functionalized, Core–Shell Gold Nanorod@Iron-Based Metal–Organic Framework (MCP-1/GNR@MIL-100(Fe)) for Photothermal Therapy

Wei-Cheng Chien, Po-Hsiu Cheng, Xu-Jun Cheng, Chi-Cheng Chuang, Yu-Ting Huang, Anilkumar T.S, Chia-Hung Liu, Yu-Jen Lu, Kevin C.-W. Wu

ACS Applied Materials & Interfaces· Volume 13· Issue 44
Publisher page

Abstract

The low vessel density and oxygen concentration in hypoxia are the main causes of reduced efficiency of anticancer therapeutics and can stimulate the tumor’s relapse. Research showed that macrophages could cross the blood-vessel barriers and reach the hypoxic regions of tumors. Using macrophages in a drug delivery system has been a promising method for tumor targeting in recent years. In this work, we successfully modified monocyte chemoattractant protein-1 (MCP-1) and iron-based metal–organic framework (MIL-100(Fe)) on the photothermal agent, gold nanorods (GNRs) (i.e., MCP-1/GNR@MIL-100(Fe)), to increase cellular uptake and biocompatibility. The results of TEM, UV–vis, and FTIR all confirmed that we’d synthesized MCP-1/GNR@MIL-100(Fe) successfully, and the MCP-1/GNR@MIL-100(Fe) also showed good biocompatibility. A transwell migration assay illustrated that our material attracted macrophages, and the material uptake amount was increased by 1.5 times after MCP-1 functionalization. It also indicated that the macrophages have a tumor-targeting ability. In the in vivo experiment, we subcutaneously implanted U251 MG cells in nude mice as a xenograft model to demonstrate the photothermal activity of MCP-1/GNR@MIL-100(Fe). With successive NIR treatment, the tumor growth could be controlled, and the tumor volume still remained below 100 mm3 after laser treatment. MCP-1/GNR@MIL-100(Fe) combined with the laser treatment showed an excellent antitumor efficacy from the histology of tumor tissues, survival rates, and bioluminescence imaging.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei 10617, Taiwan

Division of Neurosurgery, Chang Gung Memorial Hospital, No. 5, Fuxing Street, Guishan District, Taoyuan City 333, Taiwan

Department of International Graduate Program of Molecular Science and Technology, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei 10617, Taiwan

Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, No. 250, Wu-Hsing Street, Taipei 110, Taiwan

TMU Research Center of Urology and Kidney, Taipei Medical University, No. 250, Wu-Hsing Street, Taipei 110, Taiwan

Department of Urology, Shuang Ho Hospital, Taipei Medical University, No. 291, Zhongzheng Road, Zhonghe District, New Taipei City 23561, Taiwan

College of Medicine, Chang Gung University, No.259, Wenhua First Road, Guishan District, Taoyuan City 33302, Taiwan

Center for Biomedical Science and Engineering, National Tsing Hua University, 101, Section 2, Kuang-Fu Road, Hsinchu 300044, Taiwan

Division of Biomedical Engineering & Nanomedicine, National Health Research Institutes, Maoli County 350, Taiwan

Funding

Chang Gung Memorial Hospital, Linkou · Ministry of Science and Technology, Taiwan

References (74)

Show source-provided references
1. 10.1007/BF0213315610.1007/BF02133156 ↗
2. 10.1016/j.nano.2013.05.01210.1016/j.nano.2013.05.012 ↗
3. 10.1007/s10103-007-0470-x10.1007/s10103-007-0470-x ↗
4. 10.1016/j.ajme.2011.01.00110.1016/j.ajme.2011.01.001 ↗
5. 10.2217/nnm.10.8510.2217/nnm.10.85 ↗
6. 10.1016/j.tibtech.2005.12.00410.1016/j.tibtech.2005.12.004 ↗
7. 10.1016/j.biomaterials.2013.03.07710.1016/j.biomaterials.2013.03.077 ↗
8. 10.1016/S1748-0132(07)70016-610.1016/S1748-0132(07)70016-6 ↗
9. 10.1021/ja057254a10.1021/ja057254a ↗
10. Kelly K. L. · 2003
11. 10.1021/jp057170o10.1021/jp057170o ↗
12. 10.1016/j.ijpharm.2020.11964110.1016/j.ijpharm.2020.119641 ↗
13. 10.1016/j.ccr.2005.01.03010.1016/j.ccr.2005.01.030 ↗
14. 10.1073/pnas.191323411710.1073/pnas.1913234117 ↗
15. 10.1038/nnano.2009.32610.1038/nnano.2009.326 ↗
16. 10.1002/wnan.144910.1002/wnan.1449 ↗
17. 10.1088/0957-4484/19/35/35550110.1088/0957-4484/19/35/355501 ↗
18. 10.1021/jp010796410.1021/jp0107964 ↗
19. 10.1002/1521-4095(200109)13:18<1389::AID-ADMA1389>3.0.CO;2-F10.1002/1521-4095(200109)13:18<1389::AID-ADMA1389>3.0.CO;2-F ↗
20. 10.1021/cm303708p10.1021/cm303708p ↗
21. 10.1021/nn103476x10.1021/nn103476x ↗
22. 10.1039/C9TB00574A10.1039/C9TB00574A ↗
23. 10.1016/j.snb.2012.05.01910.1016/j.snb.2012.05.019 ↗
24. 10.1002/ppsc.20140000610.1002/ppsc.201400006 ↗
25. 10.1002/adma.20120169010.1002/adma.201201690 ↗
26. 10.1039/b804797a10.1039/b804797a ↗
27. 10.1021/cm048297d10.1021/cm048297d ↗
28. 10.1039/C3CS60472A10.1039/C3CS60472A ↗
29. 10.1021/ar100061710.1021/ar1000617 ↗
30. 10.1002/adma.20170683110.1002/adma.201706831 ↗
31. 10.1021/acsami.8b2022210.1021/acsami.8b20222 ↗
32. 10.1021/jm401720210.1021/jm4017202 ↗
33. 10.1038/srep4309910.1038/srep43099 ↗
34. 10.1038/srep0785110.1038/srep07851 ↗
35. Ma X. · Yale J. Biol. Med. · 2006 · 79 · 85
36. 10.1016/j.ccell.2015.10.01210.1016/j.ccell.2015.10.012 ↗
37. 10.1016/j.tem.2004.07.00210.1016/j.tem.2004.07.002 ↗
38. 10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
39. 10.7150/thno.3956010.7150/thno.39560 ↗
40. 10.1002/smll.20190501310.1002/smll.201905013 ↗
41. Wu H.-C. · J. Cancer Mol. · 2006 · 2 · 57
42. 10.1200/JCO.2006.08.541510.1200/JCO.2006.08.5415 ↗
43. 10.1016/S1470-2045(09)70240-210.1016/S1470-2045(09)70240-2 ↗
44. 10.1016/j.actbio.2020.06.01910.1016/j.actbio.2020.06.019 ↗
45. 10.1016/j.nano.2019.10214610.1016/j.nano.2019.102146 ↗
46. Balkwill F. R. · 201210.1242/jcs.116392 ↗
47. 10.1038/s41467-020-18569-410.1038/s41467-020-18569-4 ↗
48. 10.1007/s11060-020-03450-710.1007/s11060-020-03450-7 ↗
49. 10.1038/nri307310.1038/nri3073 ↗
50. 10.1073/pnas.191893711710.1073/pnas.1918937117 ↗
51. 10.7150/thno.3865910.7150/thno.38659 ↗
52. 10.3390/cancers603167010.3390/cancers6031670 ↗
53. 10.1038/s41467-020-16827-z10.1038/s41467-020-16827-z ↗
54. 10.1002/1096-9896(2000)9999:9999<::AID-PATH687>3.0.CO;2-G10.1002/1096-9896(2000)9999:9999<::AID-PATH687>3.0.CO;2-G ↗
55. 10.1002/1521-4141(200209)32:9<2393::AID-IMMU2393>3.0.CO;2-410.1002/1521-4141(200209)32:9<2393::AID-IMMU2393>3.0.CO;2-4 ↗
56. 10.1016/S0002-9440(10)63801-110.1016/S0002-9440(10)63801-1 ↗
57. 10.1089/jir.2008.002710.1089/jir.2008.0027 ↗
58. 10.1593/neo.0998810.1593/neo.09988 ↗
59. 10.1371/journal.pone.016888810.1371/journal.pone.0168888 ↗
60. 10.1038/s41388-019-1090-110.1038/s41388-019-1090-1 ↗
61. 10.3390/cancers1212372310.3390/cancers12123723 ↗
62. Choi J. · Am. J. Cancer Res. · 2020 · 10 · 2878
63. 10.1007/s12307-012-0123-x10.1007/s12307-012-0123-x ↗
64. 10.1038/s41598-020-76657-310.1038/s41598-020-76657-3 ↗
65. 10.1038/s41467-020-16789-210.1038/s41467-020-16789-2 ↗
66. 10.1038/nature1013810.1038/nature10138 ↗
67. 10.1172/JCI11793310.1172/JCI117933 ↗
68. 10.1593/neo.0628010.1593/neo.06280 ↗
69. 10.1136/gutjnl-2015-31051410.1136/gutjnl-2015-310514 ↗
70. 10.1007/s00262005060310.1007/s002620050603 ↗
71. 10.1039/C6BM00637J10.1039/C6BM00637J ↗
72. 10.1038/modpathol.2013.15310.1038/modpathol.2013.153 ↗
73. 10.1074/jbc.RA117.00129410.1074/jbc.RA117.001294 ↗
74. 10.2174/156652401666616052314393710.2174/1566524016666160523143937 ↗